{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:41:55Z","timestamp":1790869315230,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1124\/jpet.110.173294","type":"journal-article","created":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:45:11Z","timestamp":1286325911000},"page":"64-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington\u2019s Disease"],"prefix":"10.1016","volume":"336","author":[{"given":"Robin J.","family":"Kleiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida H.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Lanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Romegialli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"des Etages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.173294_bib1","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.2741\/3122","article-title":"MSK activation and physiological roles","volume":"13","author":"Arthur","year":"2008","journal-title":"Front Biosci"},{"key":"10.1124\/jpet.110.173294_bib2","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1016\/j.febslet.2005.03.089","article-title":"Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract","volume":"579","author":"Baillie","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.110.173294_bib3","series-title":"4th Annual Huntington\u2019s Disease Therapeutics Conference: A Forum for Drug Discovery and Development; 2009 April 27\u201330; Cannes, France","article-title":"In vivo validation of HDACs as therapeutic targets for HD","author":"Bates","year":"2009"},{"key":"10.1124\/jpet.110.173294_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B"},{"key":"10.1124\/jpet.110.173294_bib5","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1523\/JNEUROSCI.1039-08.2008","article-title":"Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol","volume":"28","author":"Bertran-Gonzalez","year":"2008","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.173294_bib6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/npp.2008.228","article-title":"Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons","volume":"34","author":"Bertran-Gonzalez","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.110.173294_bib7","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/jpet.110.173294_bib8","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1093\/emboj\/17.15.4426","article-title":"Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2\/p38, and may mediate activation of CREB","volume":"17","author":"Deak","year":"1998","journal-title":"EMBO J"},{"key":"10.1124\/jpet.110.173294_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0079-6603(00)64009-6","article-title":"Transcriptional regulation by cyclic AMP-responsive factors","volume":"64","author":"De Cesare","year":"2000","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"10.1124\/jpet.110.173294_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cell.2008.10.029","article-title":"Application of a translational profiling approach for the comparative analysis of CNS cell types","volume":"135","author":"Doyle","year":"2008","journal-title":"Cell"},{"key":"10.1124\/jpet.110.173294_bib11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/YPG.0b013e3283053019","article-title":"Coregulation of genes in the mouse brain following treatment with clozapine, haloperidol, or olanzapine implicates altered potassium channel subunit expression in the mechanism of antipsychotic drug action","volume":"18","author":"Duncan","year":"2008","journal-title":"Psychiatr Genet"},{"key":"10.1124\/jpet.110.173294_bib12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.4161\/cc.3.11.1246","article-title":"Structure-forming CAG\/CTG repeat sequences are sensitive to breakage in the absence of Mrc1 checkpoint function and S-phase checkpoint signaling: implications for trinucleotide repeat expansion diseases","volume":"3","author":"Freudenreich","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.110.173294_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1460-9568.2005.04545.x","article-title":"Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington\u2019s disease","volume":"23","author":"Giamp\u00e0","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.110.173294_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease","volume":"5","author":"Giamp\u00e0","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1124\/jpet.110.173294_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.nbd.2009.02.014","article-title":"Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington\u2019s disease","volume":"34","author":"Giamp\u00e0","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.110.173294_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"PDE10A inhibitor activity in preclinical models of the positive, cognitive and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173294_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.110.173294_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.molbrainres.2005.01.014","article-title":"Differential localization of MAPK-activated protein kinases RSK1 and MSK1 in mouse brain","volume":"136","author":"Heffron","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1124\/jpet.110.173294_bib19","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1111\/j.1460-9568.2004.03796.x","article-title":"Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A","volume":"20","author":"Hu","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.110.173294_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0306-4522(98)00724-6","article-title":"Administration of recombinant human activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington\u2019s disease","volume":"92","author":"Hughes","year":"1999","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.110.173294_bib21","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1074\/jbc.M308471200","article-title":"Subcellular localization of cyclic nucleotide phosphodiesterase type 10A variants, and alteration of the localization by cAMP-dependent protein kinase-dependent phosphorylation","volume":"279","author":"Kotera","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.173294_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.molcel.2004.06.034","article-title":"Expanded CAG repeats activate the DNA damage checkpoint pathway","volume":"15","author":"Lahiri","year":"2004","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.110.173294_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0169-328X(95)00139-J","article-title":"Differential regulation of mRNA levels encoding for the two isoforms of glutamate decarboxylase (GAD65 and GAD67) by dopamine receptors in the rat striatum","volume":"34","author":"Laprade","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1124\/jpet.110.173294_bib24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.biopsych.2005.01.022","article-title":"Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat","volume":"57","author":"MacDonald","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.110.173294_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1042\/BJ20041501","article-title":"MSK1 activity is controlled by multiple phosphorylation sites","volume":"387","author":"McCoy","year":"2005","journal-title":"Biochem J"},{"key":"10.1124\/jpet.110.173294_bib26","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0306-4522(88)90256-4","article-title":"Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D1 and D2 antagonists","volume":"25","author":"Morris","year":"1988","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.110.173294_bib27","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.173294_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20082234","article-title":"Dual-specificity phosphatases: critical regulators with diverse cellular targets","volume":"418","author":"Patterson","year":"2009","journal-title":"Biochem J"},{"key":"10.1124\/jpet.110.173294_bib29","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1096\/fj.07-9814","article-title":"Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death","volume":"22","author":"Roze","year":"2008","journal-title":"FASEB J"},{"key":"10.1124\/jpet.110.173294_bib30","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","article-title":"Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia","volume":"325","author":"Schmidt","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173294_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.110.173294_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.173294_bib33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.110.173294_bib34","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.110.173294_bib35","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.110.173294_bib36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation","volume":"328","author":"Threlfell","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.173294_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1006\/geno.1996.0606","article-title":"Cloning and characterization of the human type II arginase gene","volume":"38","author":"Vockley","year":"1996","journal-title":"Genomics"},{"key":"10.1124\/jpet.110.173294_bib38","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1523\/JNEUROSCI.4470-03.2004","article-title":"The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity states and electrophysiological properties of striatal medium spiny neurons recorded in vivo","volume":"24","author":"West","year":"2004","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.110.173294_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.110.173294_bib40","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1073\/pnas.0501076102","article-title":"Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.110.173294_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-9964(03)00088-4","article-title":"Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression","volume":"66","author":"Zink","year":"2004","journal-title":"Schizophr Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524461739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524461739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.173294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:23:14Z","timestamp":1740018194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524461739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0022356524461739"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.173294","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Suppression of Phosphodiesterase 10A Alters Striatal Expression of Genes Responsible for Neurotransmitter Synthesis, Neurotransmission, and Signaling Pathways Implicated in Huntington\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.173294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}